Format
Sort by
Items per page

Send to

Choose Destination

Best matches for PEGFILGRASTIM/AE:

Search results

Items: 1 to 20 of 458

1.

Appropriateness of using granulocyte colony-stimulating factor (G-CSF) for primary prophylaxis of febrile neutropenia in solid tumors.

Laali E, Fazli J, Sadighi S, Mohammadi M, Gholami K, Jahangard-Rafsanjani Z.

J Oncol Pharm Pract. 2019 Oct 15:1078155219875507. doi: 10.1177/1078155219875507. [Epub ahead of print]

PMID:
31615347
3.

Pegfilgrastim-induced fatigue and leukocytosis improved following dose reduction in a young patient with breast cancer: A case report.

Takuwa H, Tsuji W, Goto T, Otsuji T, Yotsumoto F.

Mol Clin Oncol. 2019 Oct;11(4):371-375. doi: 10.3892/mco.2019.1907. Epub 2019 Aug 7.

4.

Safety and Relative Dose Intensity of Dose-dense Doxorubicin and Cyclophosphamide Followed by Dose-dense Paclitaxel.

Nishimura M, Onoe T, Sakai H, Arase M, Watanabe S, Soyama M, Hashimoto K, Miki M, Tane K, Hirokaga K, Takao S, Matsumoto K.

Anticancer Res. 2019 Aug;39(8):4379-4383. doi: 10.21873/anticanres.13607.

PMID:
31366533
5.

Pegfilgrastim-induced hyperleukocytosis leading to hospitalization of a patient with breast cancer.

Chavda R, Herrington JD.

Proc (Bayl Univ Med Cent). 2019 Mar 20;32(2):261-262. doi: 10.1080/08998280.2018.1547873. eCollection 2019 Apr.

6.

Risk factors for neutropenia and febrile neutropenia following prophylactic pegfilgrastim.

Lee M, Yee J, Kim JY, Kim JY, An SH, Lee KE, Gwak HS.

Asia Pac J Clin Oncol. 2019 Aug;15(4):231-237. doi: 10.1111/ajco.13152. Epub 2019 Apr 17.

PMID:
30997742
7.

[Comparison of Pegfilgrastim and Filgrastim for the Primary Prophylactic Effect for Preventing Febrile Neutropenia in Patients Undergoing Rituximab with Dose-adjusted EPOCH Chemotherapy].

Kataoka T, Sakurashita H, Taogoshi T, Nishigakiuchi R, Murase T, Izumitani S, Saeki Y, Matsuo H.

Yakugaku Zasshi. 2019;139(4):629-633. doi: 10.1248/yakushi.18-00101. Japanese.

8.

[Identification of the Risk Factors for Cabazitaxel-Induced Neutropenia with Preventive Administration of Pegfilgrastim].

Kageyama A, Nakazawa Y, Ando N, Harada D, Kitamura M, Kawakubo T, Asano K.

Gan To Kagaku Ryoho. 2019 Feb;46(2):279-281. Japanese.

PMID:
30914534
9.

LA-EP2006: A Pegfilgrastim Biosimilar.

Hoy SM.

BioDrugs. 2019 Apr;33(2):229-232. doi: 10.1007/s40259-019-00348-3. Review.

PMID:
30887256
10.

Safety analysis of proposed pegfilgrastim biosimilar in Phase I and Phase III studies.

Harbeck N, Wang J, Otto GP, Gattu S, Krendyukov A.

Future Oncol. 2019 Apr;15(12):1313-1322. doi: 10.2217/fon-2018-0878. Epub 2019 Mar 5.

11.

Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia.

Waller CF, Ranganna GM, Pennella EJ, Blakeley C, Bronchud MH, Mattano LA Jr, Berzoy O, Voitko N, Shparyk Y, Lytvyn I, Rusyn A, Popov V, Láng I, Beckmann K, Sharma R, Baczkowski M, Kothekar M, Barve A.

Ann Hematol. 2019 May;98(5):1217-1224. doi: 10.1007/s00277-019-03639-5. Epub 2019 Mar 1.

12.

Oral loratadine in the management of G-CSF-induced bone pain: a pilot study.

Duggan C, Murphy L, Costello V, Leary EO, Yousif AD, Blazkova S, Dowling M.

Br J Nurs. 2019 Feb 28;28(4):S4-S11. doi: 10.12968/bjon.2019.28.4.S4.

PMID:
30811242
13.
14.

Efficacy of pegfilgrastim to support neoadjuvant dose-dense epirubicin and cyclophosphamide chemotherapy in breast cancer.

Wang X, He Y, Wang T, Xie Y, Li J, Ouyang T, Fan Z.

Support Care Cancer. 2019 Aug;27(8):3019-3025. doi: 10.1007/s00520-018-4572-8. Epub 2019 Jan 4.

PMID:
30607682
15.

[A Case of Arteritis That Developed after Pegfilgrastim Administration during Chemotherapy for Breast Cancer].

Chino T, Oba T, Yamamoto K, Takekoshi D, Iesato A, Ito T, Kanai T, Maeno K, Ito K.

Gan To Kagaku Ryoho. 2018 Dec;45(12):1771-1774. Japanese.

PMID:
30587739
16.

[Safety Profile of the Combination of Prophylactic Pegfilgrastim and Cabazitaxel for Japanese Patients with Castration Resistant Prostate Cancer].

Azuma K, Kawakami K, Yuasa T, Sugisaki T, Hashimoto K, Aoyama T, Suzuki K, Yonese J, Hama T.

Gan To Kagaku Ryoho. 2018 Dec;45(12):1737-1742. Japanese.

PMID:
30587731
17.

[Utility of Prophylactic Administration of Pegfilgrastim in Breast Cancer Chemotherapy].

Norimura S, Kontani K, Morishita A, Kubo T, Murazawa C, Hashimoto S, Hashimoto N, Kenzaki K, Miura K, Yokomise H.

Gan To Kagaku Ryoho. 2018 Dec;45(12):1729-1732. Japanese.

PMID:
30587729
18.

Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in patients with non-Hodgkin lymphoma (NADIR study).

Wolff T, Schulz H, Losem C, Reichert D, Hurtz HJ, Sandner R, Harde J, Grebhardt S, Potthoff K, Mueller U, Fietz T.

Eur J Haematol. 2019 Feb;102(2):174-181. doi: 10.1111/ejh.13189. Epub 2018 Nov 23.

PMID:
30347466
19.

First Pegfilgrastim Biosimilar Approved.

Aschenbrenner DS.

Am J Nurs. 2018 Oct;118(10):19-20. doi: 10.1097/01.NAJ.0000546389.75712.6e. No abstract available.

PMID:
30260881
20.

Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin's lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study.

Salmon JP, Smakal M, Karanikiotis C, Wojtukiewicz MZ, Omnes Y, DeCosta L, Wetten S, O'Kelly J.

Support Care Cancer. 2019 Apr;27(4):1449-1457. doi: 10.1007/s00520-018-4473-x. Epub 2018 Sep 26.

PMID:
30259136

Supplemental Content

Loading ...
Support Center